| Patent Number |
Title Of Patent |
Date Issued |
| 5883075 |
Cyclic endothelin antagonists |
March 16, 1999 |
| Disclosed are (1) a cyclic hexapeptide represented by formula I or a salt thereof: ##STR1## wherein X and Y each represent .alpha.-amino acid residues, A represents a D-acidic-.alpha.-amino acid residue, B represents a neutral-.alpha.-amino acid residue, C represents an L-.alpha. |
| 5879896 |
Method of screening for inhibitors of human thyrotropin releasing hormone (TRH) receptor |
March 9, 1999 |
| A human receptor protein capable of binding TRH, a DNA coding for said protein, use of the proetein and DNA, a method for preparing said protein, and antibodies to the protein are described.The human TRH receptor protein and the DNA coding for the protein of the present invention are use |
| 5879708 |
Stabilized pharmaceutical composition |
March 9, 1999 |
| The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, |
| 5876756 |
Microcapsule containing amorphous water-soluble 2-piperazinone-1-acetic acid compound |
March 2, 1999 |
| A microcapsule contains a pharmaceutically effective amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof and a polymer binder and a method of preparing said microcapsule. The microcapsule is produced by dispersing in an aqueous phase a dispersion of the amor |
| 5874277 |
Proteins, their production and use |
February 23, 1999 |
| This invention relates to a novel calpain having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a pharmac |
| 5874247 |
Protein disulfide isomerase and method of using |
February 23, 1999 |
| Protein disulfide isomerase, which catalyzes the exchange reaction between sulfhydryl and disulfide in a protein for formation of the most stable natural type disulfide bonds, is useful for formation of natural type disulfide bonds in a protein which is produced in a prokaryotic cell. |
| 5874245 |
Human G-protein coupled receptor (HIBCD07) |
February 23, 1999 |
| Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such p |
| 5868234 |
Transfer device for transferring solid articles |
February 9, 1999 |
| A transfer device for transferring solid articles, comprising: a cylindrical member which has a supply opening formed at one end portion and a discharge opening formed at the other end portion, such that an angle formed between an axis of the cylindrical member and a horizontal plane |
| 5866657 |
Primer composition |
February 2, 1999 |
| In order to provide a general-purpose aqueous primer composition requiring no organic solvent and capable of improving adhesive strength and durability while ensuring an adequate application life required for the work of primer coating process, a primer composition according to the p |
| 5866567 |
Diazepinones, their production and use |
February 2, 1999 |
| A compound of the general formula ##STR1## wherein A represents a benzene ring, B represents a 6-membered hydrocarbon ring; X represents a lower alkylene, carbonyl or sulfonyl; Y represents a bond, oxygen or >N--R.sup.1, R.sup.1 represents H or an alkyl group, R represents H, |
| 5861284 |
Method for producing a biologically active recombinant cysteine-free parathyroid hormone (1-34) |
January 19, 1999 |
| A cysteine-free peptide is produced by producing a fused protein comprising a protein having cysteine at its N-terminal and a cysteine-free peptide ligated to the N-terminal and subsequently subjecting the fused protein to a reaction for cleaving the peptide linkage. |
| 5858787 |
DNA encoding PACAP receptor protein and method for preparing said protein |
January 12, 1999 |
| This invention discloses a PACAP receptor protein or a salt thereof, a DNA comprising a DNA fragment coding for the protein, a method for preparing the protein, antibody against the protein and use of the protein, DNA and antibodies. A PACAP receptor protein was purified from the bovine |
| 5858779 |
Monoclonal antibody, hybridoma, their production and use thereof |
January 12, 1999 |
| A monoclonal antibody is produced from a cloned hybridoma, and the monoclonal antibody combines specifically with basic fibroblast growth factor (bFGF). Therefore, the monoclonal antibody can be advantageously used for assay reagents on bFGF or for purification of bFGF. |
| 5856138 |
Human parathyroid hormone muteins and production thereof |
January 5, 1999 |
| Disclosed are (1) a human parathyroid hormone mutein which comprises at least one modification selected from the group consisting of (i) deletion of 3 to 6 amino acid residues on the N-terminal side in the amino acid sequence of human parathyroid hormones, (ii) substitution of another |
| 5855914 |
Granules having core and their production |
January 5, 1999 |
| Granules having a core are produced by spraying core granules with a dispersion of a low substituted hydroxypropylcellulose (L-HPC), and, if necessary, simultaneously applying a dusting powder. The granules having a core thus obtained exhibit increased granule strength and improved d |
| 5854313 |
Fine particles of high heat resistant polymer and epoxy esters |
December 29, 1998 |
| Fine particles of high heat resistant polymer obtained by emulsion polymerization or seeded polymerization of at least one epoxy ester (C) having two or more unsaturated bonds in one molecule and at least one reactive monomer (D) having at least one unsaturated double bond in one mol |
| 5852177 |
Basic fibroblast growth factor (bFGF) muteins |
December 22, 1998 |
| A mutein of basic fibroblast growth factors (bFGF) possesses fibroblast growth promoting activity, growth stimulating activity of capillary endothelial cells and angiogenic activity, has high stability and is low toxicity. And therefore, the present mutein is advantageously used as a |
| 5852039 |
Pharmaceutical composition containing quinoline or quinazoline derivatives |
December 22, 1998 |
| The present invention provides a pharmaceutical composition for inhibiting bone resorption or for preventing or treating osteoporosis which comprises a quinoline or quinazoine derivative as an active ingredient. |
| 5851990 |
bFGF mutein and its production |
December 22, 1998 |
| A mutein resulting from substitution of cysteins for at least one of the constitutional amino acids has a high stability, and can serve well as a pharmaceutical, such as a healing promoting agent for wounds. |
| 5851451 |
Production of microspheres |
December 22, 1998 |
| Disclosed is a method of producing microspheres which comprises subjecting a w/o/w emulsion or o/w emulsion to an in-water drying method under the following conditions:1) the amount of microspheres per m.sup.3 of an external aqueous phase is about 0.1 to about 500 kg,2) the square root o |
| 5849768 |
.alpha.-unsaturated amines, their production and use |
December 15, 1998 |
| .alpha.-Unsaturated amines of the formula: ##STR1## wherein X.sup.1 and X.sup.2 are such that one is an electron-attracting group with the other being a hydrogen atom or an electron-attracting group; R.sup.1 is a group attached through a nitrogen atom; R.sup.2 is a hydrogen atom |
| 5846562 |
Oral composition of fumagillol derivative |
December 8, 1998 |
| The present invention relates to a pharmaceutical composition for oral administration in which a fumagillol derivative is stabilized and exhibits remarkable antiangiogenesis activity in oral administration. |
| 5840917 |
Phosphorylamides, their preparation and use |
November 24, 1998 |
| A phosphorylamide derivative represented by the general formula (I): ##STR1## wherein R represents an amino group that may be substituted, or a salt thereof, possesses potent antibacterial activity against Helicobacter bacterium, especially Helicobacter pylori, and is useful for prev |
| 5840881 |
Composition containing a water-insoluble or slightly water-soluble compound with enhanced water- |
November 24, 1998 |
| A composition is disclosed comprising a water-insoluble or slightly water-soluble compound and a branched cyclodextrin-carboxylic acid. The branched cyclodextrin-carboxylic acid significantly increases the water-solubility of the compound. Also disclosed is a method of enhancing wate |
| 5840732 |
Imidazopyridine or imidazopyrimidine compounds, their production and use |
November 24, 1998 |
| This invention provides a new condensed imidazole compound possessing inhibitory activity of adhesion molecule expression.This invention also provides a therapeutic and prophylactic agent for diabetic nephritis and/or autoimmune disease and an immunosuppressor for organ transplantation. |
| 5837281 |
Stabilized interface for iontophoresis |
November 17, 1998 |
| An interface is formed by incorporating (1) a mixture comprising a water-soluble protein and a drug into a matrix, or preferably (2) a mixture comprising a water-soluble protein and a drug to a porous matrix coated with a cationic surfactant or other ionic surfactant. The coating amo |
| 5834463 |
Condensed heterocyclic compounds, their production and use |
November 10, 1998 |
| Compounds represented by the formula: ##STR1## wherein ring A is benzene; Ar is aromatic group; R.sup.1, R.sup.2 and R.sup.3 each stands for H, acyl, hydrocarbon or heterocyclic, or R.sup.2 and R.sup.3, taken together, may form non-aromatic cyclic hydrocarbon; X is methylene or c |
| 5824339 |
Effervescent composition and its production |
October 20, 1998 |
| An effervescent composition comprising a core-shell powder consisting of a fine granular core spray-coated with a liquid mixture containing a water-soluble polymer such as hydroxypropylcellulose or hydroxypropylmethylcellulose, and at least one physiologically active substance, espec |
| 5817819 |
Condensed-ring thiophene derivatives, their production and use |
October 6, 1998 |
| A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the preven |
| 5817056 |
Prefilled syringe |
October 6, 1998 |
| A prefilled syringe capable of separate storage of different substances before use. It includes a tubular body having an injection needle at one end and a plunger at the other end, and a partition slidable axially in the tubular body. The partition includes a front part and a rear part |
| 5814642 |
Tetracyclic condensed heterocyclic compounds their production, and use |
September 29, 1998 |
| A novel compound of the formula ##STR1## wherein Ar represents a tetracyclic fused heterocyclic group which may be substituted; R.sup.1 represents H or a hydrocarbon group which may be substituted; Y represents an amino acid or nitrogen-containing saturated heterocyclic group whi |
| 5814342 |
Prolonged release microcapsules |
September 29, 1998 |
| This invention provides a microcapsule designed for zero order release of a physiologically active polypeptide over a period of at least two months, which is produced by preparing a water-in-oil emulsion comprising an inner aqueous layer containing about 20 to 70% (w/w) of said polypepti |
| 5814324 |
Injectable composition and a method of producing the same |
September 29, 1998 |
| An injectable oil-in-water emulsion composition comprises an antifungal triazole compound of the following formula (I) ##STR1## wherein Ar represents a substituted phenyl group; R.sup.1 and R.sup.2 represent, independently, a hydrogen atom or a lower alkyl group, or R.sup.1 and R |
| 5811263 |
DNA encoding human endothelin-3, and use thereof |
September 22, 1998 |
| A cloned DNA molecule is disclosed. The DNA molecule encodes a human endothelin-3 protein having the amino acid sequence: Glu-Gly-Ala-Pro-Glu-His-His-Arg-Ser-Arg-Arg-Cys-Thr-Cys-Phe-Thr-Tyr-Lys-As p-Lys-Glu-Cys-Val-Tyr-Tyr-Cys-His-Leu-Asp-Ile-Ile-Trp-Ile-Asn-Thr-Pro-Glu or any portion |
| 5804601 |
Aromatic hydroxamic acid compounds, their production and use |
September 8, 1998 |
| The present invention relates to a compound of the formula: ##STR1## wherein Ar represents an optionally substituted aromatic group; Q represents a divalent aliphatic hydrocarbon group; R.sub.1 represents hydrogen, cyano, an optionally substituted hydrocarbon group, a group of th |
| 5804415 |
Prostaglandin E receptors, their DNA and production |
September 8, 1998 |
| Disclosed are (1) a protein capable of receiving PGE, (2) a recombinant DNA coding for said protein, (3) a vector having said DNA, (4) a transformant carrying said vector, and (5) a method for producing said protein wherein said transformant is cultured in a culture medium, the protein b |
| 5801147 |
Polypeptides and use thereof |
September 1, 1998 |
| Disclosed are (1) a polypeptide represented by formula (I), or a pharmaceutically acceptable amide, ester or salt thereof:wherein X is hydrogen atom; or a lower alkyl group which may be substituted with a member selected from the group consisting of hydroxy group, substituted or unsubsti |
| 5792780 |
Azole compounds, their production and use |
August 11, 1998 |
| The present invention provides an azole compound represented by the formula (I): ##STR1## , wherein Ar is an optionally-substituted phenyl group; R.sup.1 and R.sup.2 are, the same or different, a hydrogen atom or a lower alkyl group, or R.sup.1 and R.sup.2 may combine together to |
| 5786352 |
Cyclic compounds, their production and use |
July 28, 1998 |
| Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the sa |
| 5783635 |
Unsaturated polyester resin composition |
July 21, 1998 |
| An unsaturated polyester resin composition which comprises 100 parts by weight of a resin mixture comprising 25 to 80 parts by weight of an unsaturated polyester, 20 to 60 parts by weight of a comonomer and 1 to 10 parts by weight of a particulate crosslinked polymer and 100 to 400 parts |
| 5770772 |
Intermediates for the preparation of aminocoumaran derivatives |
June 23, 1998 |
| Disclosed are intermediates for the preparation of novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are |
| 5770590 |
Cyclic compounds, their prudiction and use |
June 23, 1998 |
| Novel compounds of the following general formula or salts thereof. ##STR1## wherein Ring M is a heterocyclic ring having --N.dbd.C<, --CO--N< or --CS--N< as the partial structure --X . . . Y<; R.sup.a and R.sup.b are bonded to each other to form Ring A, or they are the sa |
| 5770438 |
Process for enantioselective hydrolysis of .alpha.-(2-amino)-phenyl-benzenemethanol ester type c |
June 23, 1998 |
| A process for producing an optically active form of a compound of formula (I) ##STR1## wherein R.sub.1 represents hydrogen or a hydrocarbon group that may be substituted; R.sub.2 and R.sub.3 independently represent hydrogen, a hydrocarbon group that may be substituted, or a heter |
| 5767121 |
Pyridine derivatives, their production and use |
June 16, 1998 |
| There is disclosed a pharmaceutical composition for providing antiinflammatory, antipyretic, analgesic, antiallergic, immunosuppressing or immunomodulating activity which comprises a pyridine derivative of the formula (I): ##STR1## wherein R is an optionally substituted pyridine |
| 5763619 |
Process for the production of tetrazolyl compounds |
June 9, 1998 |
| Disclosed is a method for removing a protective group of an N-protected tetrazolyl compound which comprises reacting said N-protected tetrazolyl compound with a mineral acid under substantially anhydrous conditions in the presence of an alcohol, insuring a high reaction yield of the obje |
| 5756600 |
Urethane-modified epoxy vinyl ester resin |
May 26, 1998 |
| A composition useful as a sheet or bulk molding compound comprises a urethane-modified vinyl ester resin (A), or acid-addition vinyl ester resn (A') obtained by reacting the hydroxyl groups in (A) with a polybasic acid anhydride (B), and a double bond(s)-containing monomer (C), wherein ( |
| 5756295 |
DNA primer and a method for screening DNAS |
May 26, 1998 |
| DNA primers each having a nucleotide sequence substantially complementary to a nucleotide sequence which codes for Gly-Lys-Arg, Gly-Lys-Lys or Gly-Arg-Arg; methods for amplifying a polynucleotide which codes for a peptide or a precursor protein thereof using said DNA primer; screening |
| 5753664 |
Heterocyclic compounds, their production and use |
May 19, 1998 |
| A novel compound of the formula:wherein A is a condensed pyrimidinone or condensed pyridazinone ring; Ar.sup.1 and Ar.sup.2 are independently a ring; Z is a divalent group, or a salt thereof which have an excellent antitumor activity. |
| 5750551 |
Treatment for viral diseases |
May 12, 1998 |
| An angiotensin II antagonist compound is administered to mammals with viral disease. This administration ameliorates virus-associated cell injuries, producing therapeutic effects in viral diseases. This compound is also useful for the prevention of such diseases. |
| 5750349 |
Antibodies to .beta.-amyloids or their derivatives and use thereof |
May 12, 1998 |
| According to this invention, antibodies which are useful and novel in that they have binding specificity to .beta.-amyloids or derivatives thereof, namely recognize the N-terminal, the C-terminal or central portions of the .beta.-amyloids, respectively, were obtained. By combining these |
